FDA Approves Priority Review of Merck's Zolinza (Vorinostat)

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

FDA Approves Priority Review of Merck's Zolinza (Vorinostat)

WHITEHOUSE STATION, New Jersey—FDA has granted priority review status to Merck's New Drug Application for Zolinza (vorinostat, also known as suberoylanilide hydroxamic acid or SAHA) for the treatment of advanced cutaneous T-cell lymphoma (CTCL). A pivotal phase IIb trial showed activity in CTCL patients who had failed a median of three previous therapies. Zolinza is potentially the first in a new class of therapies, the histone deacetylase inhibitors.

Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
2 experts in this video
2 experts in this video
Related Content